All Blogs

Apr 12, 2024

Unlike traditional antipsychotic medications that block dopamine receptors, CVL-231 selectively modulates the M4 receptor in the brain and provides antipsychotic effects without the need for titration. CVL-231, a once-daily medication, with enhanced potential for treatment adherence, seeks to bypass gastrointes...

Apr 12, 2024

KarXT, likely to receive the nod from the US FDA by late 2024, will significantly impact the market with the potential to reduce the positive, negative, and cognitive symptoms of schizophrenia. The long-term data is encouraging, signaling that KarXT is not associated with “burdensome side effects” the major imp...

Apr 12, 2024

In the landscape of schizophrenia treatment, there are significant gaps that affect patients' lives profoundly. From the foggy terrain of early detection, where symptoms blur the lines between schizophrenia and other mental health conditions, to the daunting landscape of treatment resistance and relapse, where stan...

Apr 12, 2024

LYN-005’s once-weekly dosing regimen reduces the pill burden for individuals with schizophrenia and schizoaffective disorders compared to traditional daily medications such as Risperdal. A unique capsule design consisting of six polymeric arms connected to a flexible core, encapsulated in a folded star-shaped f...

Apr 12, 2024

Despite the urgent need for novel treatments, drug development for cognitive impairment associated with schizophrenia has been challenging, due to limited understanding, high trial failures, and few potential targets in the treatment regime. Iclepertin (BI 425809), an investigational asset, is a GlyT1 inhibitor...

Apr 12, 2024

Brilaroxazine, developed by Reviva Therapeutics, exhibits potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia. Brilaroxazine’s pharmacological profile sets it apart from traditional antipsychotics. Operating as a partial agonist at D2/3/4 and 5-HT1A/2A recept...

Apr 12, 2024

Glaucoma, often dubbed as the “silent thief of sight,” poses a significant challenge in the domain of ophthalmology. Glaucoma treatment has made significant strides, yet several unmet needs persist, posing challenges to effective management and vision preservation. By prioritizing early detection, embracing persona...

Apr 10, 2024

Glioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous system (CNS). Despite advancements in diagnostic approaches and the development of new therapies, the prognosis for glioblastoma patients remains notably poor, with limited improvement observed. At AACR ...

Apr 11, 2024

Carl Zeiss Meditec AG Completed Acquisition of Dutch Ophthalmic Research Center (D.O.R.C); Companies Unite to Shape Ophthalmology Market  On April 04, 2024, Carl Zeiss Meditec AG announced that it acquired D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. T...

Apr 10, 2024

The findings presented at the 2024 AACR conference revealed that among patients diagnosed with PIK3Ca-mutated MSS mCRC (n = 22), three patients attained a partial response (PR). Additionally, one more patient with PIK3Ca-mutated mCRC maintained stable disease (SD). The study successfully achieved its primary endpoi...